Literature DB >> 15221282

[Therapy induced regressive changes of prostate cancer].

B Helpap1, J Köllermann.   

Abstract

Regressive changes following pretreatment of prostate cancer may represent a big challenge for the histopathologist not familiar with the assessment of pretreated specimens. Characteristic changes after antiandrogen therapy in non-malignant prostate tissue include glandular atrophy, basal cell prominence and/or basal cell hyperplasia as well as a hypercellular stroma. Morphologic changes in prostate cancer include cytoplasmic clearing and vacuolization, nuclear pyknosis and even complete cell destruction. On the glandular level, changes are characterized by various degrees of involutional changes, ranging from almost non-regressive tumor glands to complete glandular disruption with scattered isolated tumor cells dispersed in the stroma. Knowledge about these changes, the selective use of immunohistochemistry as well as a very thorough histological workup is essential for the correct assessment of these specimens.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15221282     DOI: 10.1007/s00292-004-0708-3

Source DB:  PubMed          Journal:  Pathologe        ISSN: 0172-8113            Impact factor:   1.011


  29 in total

Review 1.  Overview consensus statement. Newer approaches to androgen deprivation therapy in prostate cancer.

Authors:  Peter R Carroll; Philip W Kantoff; Steven P Balk; Myles A Brown; Anthony V D'amico; Daniel J George; Gary D Grossfeld; Candace S Johnson; William Kevin Kelly; Laurence Klotz; W Robert Lee; Deborah P Lubeck; David G Mcleod; William K Oh; Alan Pollack; Oliver Sartor; Matthew R Smith; Carol Hart
Journal:  Urology       Date:  2002-09       Impact factor: 2.649

2.  Neuroendocrine differentiation and short-term neoadjuvant hormonal treatment of prostatic carcinoma with special regard to tumor regression.

Authors:  J Köllermann; B Helpap
Journal:  Eur Urol       Date:  2001-09       Impact factor: 20.096

3.  Nondetected tumor (pT0) after prolonged, neoadjuvant treatment of localized prostatic carcinoma.

Authors:  J Köllermann; U Feek; H Müller; U Kaulfuss; U Oehler; B Helpap; M W Köllermann
Journal:  Eur Urol       Date:  2000-12       Impact factor: 20.096

4.  Neoadjuvant hormonal therapy prior to radical prostatectomy: the European experience.

Authors:  F M Debruyne; W P Witjes
Journal:  Mol Urol       Date:  2000

5.  Pathological staging and biochemical recurrence after neoadjuvant androgen deprivation therapy in combination with radical prostatectomy in clinically localized prostate cancer: results of a phase II study.

Authors:  M S Cookson; P C Sogani; P Russo; J Sheinfeld; H Herr; G Dalbagni; V E Reuter; C B Begg; W R Fair
Journal:  Br J Urol       Date:  1997-03

6.  Pathology of androgen deprivation therapy in prostate carcinoma. A comparative study of 173 patients.

Authors:  F Civantos; M A Marcial; E R Banks; C K Ho; V O Speights; P A Drew; W M Murphy; M S Soloway
Journal:  Cancer       Date:  1995-04-01       Impact factor: 6.860

7.  Follow-up of nondetectable prostate carcinoma (pT0) after prolonged PSA-monitored neoadjuvant hormonal therapy followed by radical prostatectomy.

Authors:  Jens Köllermann; Jörg Caprano; Anke Budde; Helga Weidenfeld; Michael Weidenfeld; Werner Hopfenmüller; Burkhard Helpap
Journal:  Urology       Date:  2003-09       Impact factor: 2.649

Review 8.  Use of neoadjuvant and adjuvant therapy to prevent or delay recurrence of prostate cancer in patients undergoing surgical treatment for prostate cancer.

Authors:  Leonard G Gomella; Ilia Zeltser; Richard K Valicenti
Journal:  Urology       Date:  2003-12-29       Impact factor: 2.649

9.  Histologic changes in prostate carcinomas treated with leuprolide (luteinizing hormone-releasing hormone effect). Distinction from poor tumor differentiation.

Authors:  D M Smith; W M Murphy
Journal:  Cancer       Date:  1994-03-01       Impact factor: 6.860

10.  Clinical and pathobiological effects of neoadjuvant total androgen ablation therapy on clinically localized prostatic adenocarcinoma.

Authors:  O A Armas; A G Aprikian; J Melamed; C Cordon-Cardo; D W Cohen; R Erlandson; W R Fair; V E Reuter
Journal:  Am J Surg Pathol       Date:  1994-10       Impact factor: 6.394

View more
  1 in total

1.  [Regressive changes after short-term neoadjuvant antihormonal therapy in prostatic carcinoma: the value of Gleason grading].

Authors:  R Grobholz; A Riester; C G Sauer; M Siegsmund
Journal:  Pathologe       Date:  2006-02       Impact factor: 1.011

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.